Literature DB >> 24575142

Selection of best door-to-cardiac regeneration (D2CR) time.

Mohaddeseh Behjati1.   

Abstract

In spite of great progress in the treatment of acute coronary syndrome (ACS) events in reperfusion era, patients are still at risk for development of heart failure due to negative remodeling. Thus, the importance of regenerative therapies in parallel with reperfusion strategies is fundamental. A key feature in this case is obtaining the most appropriate door-to-cardiac regeneration (D2CR) time. This golden time in which fresh stem cells can invade scare-prone tissue could be defined as door-to-cardiac stem cell (D2CSC) plus door-to-cardiac regeneration (D2CR) time. Application of stem cells in this golden time allows comprehensive regeneration and reconstruction. Therefore, the aim of this study was to plan the outlines of simultaneous application of cellular and vascular reconstruction strategies.

Entities:  

Keywords:  Cardiac Regeneration; Golden Time; Stem Cell

Year:  2013        PMID: 24575142      PMCID: PMC3933063     

Source DB:  PubMed          Journal:  ARYA Atheroscler        ISSN: 1735-3955


  6 in total

1.  Myocardial blood flow and infarct size after CD133+ cell injection in large myocardial infarction with good recanalization and poor reperfusion: results from a randomized controlled trial.

Authors:  Alessandro Colombo; Massimo Castellani; Emanuela Piccaluga; Enrico Pusineri; Simone Palatresi; Virgilio Longari; Cristina Canzi; Elisabetta Sacchi; Edoardo Rossi; Roberto Rech; Paolo Gerundini; Maurizio Viecca; Giorgio Lambertenghi Deliliers; Paolo Rebulla; Davide Soligo; Rosaria Giordano
Journal:  J Cardiovasc Med (Hagerstown)       Date:  2011-04       Impact factor: 2.160

Review 2.  Mesenchymal stem cells: promising for myocardial regeneration?

Authors:  Ewa Przybyt; Martin C Harmsen
Journal:  Curr Stem Cell Res Ther       Date:  2013-07       Impact factor: 3.828

3.  Myoblast transplantation for heart failure.

Authors:  P Menasché; A A Hagège; M Scorsin; B Pouzet; M Desnos; D Duboc; K Schwartz; J T Vilquin; J P Marolleau
Journal:  Lancet       Date:  2001-01-27       Impact factor: 79.321

4.  Intracoronary infusion of bone marrow-derived mononuclear cells abrogates adverse left ventricular remodelling post-acute myocardial infarction: insights from the reinfusion of enriched progenitor cells and infarct remodelling in acute myocardial infarction (REPAIR-AMI) trial.

Authors:  Volker Schächinger; Birgit Assmus; Sandra Erbs; Albrecht Elsässer; Werner Haberbosch; Rainer Hambrecht; Jiangtao Yu; Roberto Corti; Detlef G Mathey; Christian W Hamm; Torsten Tonn; Stefanie Dimmeler; Andreas M Zeiher
Journal:  Eur J Heart Fail       Date:  2009-10       Impact factor: 15.534

5.  Percutaneous, transendocardial injection of bone marrow-derived mononuclear cells in heart failure patients following acute ST-elevation myocardial infarction: ALSTER-Stem Cell trial.

Authors:  Christian-H Heeger; Kai Jaquet; Holger Thiele; Yanuar Zulkarnaen; Alessandro Cuneo; Dirk Haller; Dietmar Kivelitz; Tobias Schmidt; Korff Krause; Andreas Metzner; Carsten Schneider; Karl-Heinz Kuck; Martin W Bergmann
Journal:  EuroIntervention       Date:  2012-10       Impact factor: 6.534

6.  Enhanced mobilization of the bone marrow-derived circulating progenitor cells by intracoronary freshly isolated bone marrow cells transplantation in patients with acute myocardial infarction.

Authors:  R G Turan; I Bozdag-T; C H Turan; J Ortak; I Akin; S Kische; H Schneider; M Rauchhaus; T C Rehders; T Kleinfeldt; C Belu; S Amen; T Hermann; S Yokus; M Brehm; S Steiner; T Chatterjee; K Sahin; C A Nienaber; H Ince
Journal:  J Cell Mol Med       Date:  2012-04       Impact factor: 5.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.